Progress in the application of PD-(L)1 PET-targeted nuclide probes for tumor immunotherapy-related studies

VernacularTitle:肿瘤免疫治疗相关PD-(L)1 PET靶向核素探针应用研究进展
Author: Xi MENG ¹ ; Hongfu SUN ; Wei HUANG
Author Information

1. 山东省肿瘤防治研究院（山东省肿瘤医院）放疗科　山东第一医科大学（山东省医学科学院），济南　250117
Keywords: programmed death receptor-1/programmed death receptor-ligand 1; Molecular imaging; Positron emission computed tomography tracer; Immunotherapy
From: Chinese Journal of Radiological Medicine and Protection 2024;44(2):158-162
CountryChina
Language:Chinese
Abstract: Immunotherapy has entered the clinical treatment for various tumors, among which the blockade therapy of PD-1/PD-L1 immune checkpoint is currently the most important tumor immunotherapy method. At present, immunohistochemical method are used in clinical practice to detect PD-L1 expression in tumor patients and screen for indications. However, this method is constrained by factors such as heterogeneity, dynamic changes in PD-L1 expression, and limited sample collection. PD-(L)1 PET imaging utilizes radiolabeled molecules to non-invasively assess PD-(L)1 expression in space and time, and complementary use with IHC has theoretically incomparable advantages. This article reviews the latest progress in the PD-(L)1 probe molecular imaging principles, clinical research and existing problems.